Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Leflunomide in polymyalgia rheumatica during corticosteroid tapering
NL-OMON59192Phase 3Recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of leflunomide in polymyalgia rheumatica (PMR), sponsored by University Medical Center Groningen. Primary endpoint: Time to first relapse. Started Sep 2024; status: recruiting.
02
Drugs
leflunomide
03
Conditions
polymyalgia rheumatica (PMR)
Beyond the preview
Go deeper on NL-OMON59192.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59192.